# Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

> **NCT02605915** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 98 (estimated)

## Conditions studied

- HER2-Positive Metastatic Breast Cancer
- HER2-Negative Metastatic Breast Cancer
- Locally Advanced or Early Breast Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Carboplatin
- **DRUG:** Docetaxel
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab
- **DRUG:** Trastuzumab emtansine
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02605915
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-31
- **Primary completion:** 2019-11-13
- **Final completion:** 2019-11-13
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02605915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02605915, "Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02605915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*